CDKN2A and glioma: Indeed, we were able to identify proliferating MCs in both Ntv-a- and Gtv-a Arf−/− mouse gliomas as compared with non-tumor tissue (Figure 3A), with an average of 7% and 4% of proliferative MCs, respectively (Figure 3B).